Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
A case study of the effectiveness an after-hours telemedicine service at a skilled nursing facility (SNF) showed the facility hospitalizations decrease by 18 percent while saving more than $1.5 million in Medicare costs.
On the heels of a new $350 million investment from private equity group The Carlyle Group, One Medical is setting its sights even higher—aiming to reduce healthcare spending by 10 percent, CNBC reported.
The Duke Clinical Research Institute in Durham, North Carolina, and Cerner partnered to develop a cardiac risk app that shares patient information with physicians about risk factors associated with heart disease and stroke.
The family of deceased rock star Prince is suing a doctor they said prescribed pain pills, claiming the physician did not treat him for opiate addiction and bears some responsibility for his April 2016 death.
Gene therapy company bluebird bio and cancer immunotherapy company Gritstone Oncology are working together to research, develop and produce a cancer treatment product that will use cell therapy.
Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025.
Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.
The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%.
